13F Holdings
中文EN

GANX Gain Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1819411 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.3%
TTM EPS YoY31.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-223.9%
ROA-148.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.3%
Debt / equity0.03x
Current ratio5.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$55,180$140,108$164,994
R&D expense$10.21M$10.79M$11.52M$8.38M$7.16M
SG&A expense$8.50M$9.56M$10.79M$9.54M$6.83M
Operating income-$18.71M-$20.35M-$22.25M-$17.78M-$13.83M
Interest expense————$0
Pretax income-$19.30M-$19.87M-$22.19M-$17.50M-$13.89M
Income tax$861,118$536,815$79,275$92,976$4,008
Net income-$20.16M-$20.41M-$22.27M-$17.59M-$13.89M
EBITDA-$18.62M-$20.27M-$22.17M-$17.71M-$13.81M
EPS (basic)-0.61-0.89-1.71-1.48-1.37
EPS (diluted)-0.61-0.89-1.71-1.48-1.37
Weighted avg. shares (diluted)32.97M22.88M13.01M11.88M10.17M
Banking
Net interest income——$494,234$375,357$12,495
Balance sheet
Cash & equivalents$20.84M$10.42M$11.83M$7.34M$36.91M
Short-term investments——$5.00M$12.83M—
Current assets$22.24M$11.60M$17.78M$21.09M$37.72M
PP&E, net$74,916$103,619$125,962$144,379$105,986
Intangibles$102,837————
Total assets$22.82M$12.12M$18.61M$24.10M$38.99M
Current liabilities$3.35M$3.91M$4.95M$4.13M$2.55M
Short-term debt$100,869$110,177$118,797$108,135$103,826
Long-term debt$300,084$328,327$449,053$495,258$590,468
Total debt$400,953$438,504$567,850$603,393$694,294
Total liabilities$4.25M$4.78M$6.03M$5.22M$4.17M
Shareholders' equity$18.56M$7.34M$12.58M$18.88M$34.82M
Net debt-$20.44M-$9.98M-$11.26M-$6.74M-$36.22M
Shares outstanding42.07M27.13M16.21M11.88M11.88M
Cash flow statement
Operating cash flow-$18.47M-$18.87M-$18.87M-$14.69M-$12.37M
Capital expenditure—$22,493$15,358$118,953$94,212
Free cash flow—-$18.90M-$18.88M-$14.81M-$12.46M
Investing cash flow—$4.98M$10.22M-$14.77M-$94,212
Financing cash flow$28.45M$13.01M$12.64M-$78,774$41.77M
Depreciation & amortization$94,046$84,071$83,579$64,168$15,484
Stock-based compensation$1.80M$2.39M$3.26M$1.53M$839,371

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.